



Market Announcement

17 February 2021

Resonance Health Limited (ASX: RHT) – Trading Halt

Description

The securities of Resonance Health Limited ('RHT') will be placed in trading halt at the request of RHT, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Friday, 19 February 2021 or when the announcement is released to the market.

Issued by

Daniel Nicholson

Adviser, Listings Compliance (Perth)

17 February 2021

ASX Limited
Level 40 Central Park
152 - 158 St Georges Terrace
PERTH WA 6000

Via email - tradinghaltspert@asx.com.au & Sean.Maloney@asx.com.au

Dear Sean,

Trading Halt

Pursuant to ASX Listing Rule 17.1, Resonance Health Limited (ASX Code: RHT) ("Company") requests that an immediate trading halt be put on its securities.

The trading halt is requested pending the release by the Company of a further ASX announcement in relation to a regulatory approval that affects the Company ("Purpose").

In accordance with Listing Rule 17.1, the Company advises:

- a) The trading halt is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make a material announcement to the market in relation to the Purpose.
- b) The trading halt is to last until the Company releases the further announcement, or the commencement of trading on Friday, 19 February 2021.
- c) The Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

Please call the undersigned if you have any queries in relation to this request.

Yours faithfully



Agha Shahzad Pervez
Company Secretary